Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04204811 · ClinicalTrials.gov registry record · NA

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

A NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT04204811: Active NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT04204811 is a NA study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04204811, a NA study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

Primary Outcome

Study will be considered feasible if the cohort has a median completion of 70% or more

Interventions

  • OTHER Prehabilitation

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-12-16
Est. Completion 2026-12-16
Phase NA
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the registry record for NCT04204811 still lists

NCT04204811 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower).

The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prehabilitation is the first listed.

NCT04204811 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04204811 about?

NCT04204811 is a clinical study titled "Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy". The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

What is the current status of trial NCT04204811?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2019-12-16. Estimated completion is 2026-12-16.

What conditions does trial NCT04204811 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Stage IV Ovarian Cancer.

What interventions are being tested in trial NCT04204811?

The interventions under investigation include: Prehabilitation (OTHER).

Who is sponsoring clinical trial NCT04204811?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04204811 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04204811's enrollment target sits among peer trials

22 276th of 322 higher than 44 of 322 other Ovarian Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04204811, the US trial registry maintained by the National Library of Medicine. NCT04204811 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.